Amicus Therapeutics, Inc.
FOLDNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for FOLD. That does not mean none is planned.
Get an email about FOLD's next catalysts
Track Amicus Therapeutics (FOLD) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
How FOLD's past catalysts played out
Market Overview
Stock performance and key metrics
Amicus Therapeutics, Inc. is an American biopharmaceutical company based in Princeton, New Jersey. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates. As of April 2026, Amicus Therapeutics is a subsidiary of BioMarin Pharmaceutical.
WebsiteATB200
Pompe Disease
migalastat hydrochloride
Fabry Disease
AT2221
Pompe Disease (Late-onset)
Agalsidase Beta
Fabry Disease
duvoglustat
Pompe Disease
Afegostat tartrate
Gaucher Disease, Type 1
migalastat HCl
Fabry Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ATB200 | Phase 3 | Pompe Disease | - | - |
migalastat hydrochloride | Phase 3 | Fabry Disease | - | - |
AT2221 | Phase 3 | Pompe Disease (Late-onset) | - | - |
Agalsidase Beta | Phase 2 | Fabry Disease | - | - |
duvoglustat | Phase 2 | Pompe Disease | - | - |
Afegostat tartrate | Phase 2 | Gaucher Disease, Type 1 | - | - |
migalastat HCl | Phase 2 | Fabry Disease | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Amicus Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Amicus Therapeutics, Inc.'s (FOLD) pipeline across Phase 3, Phase 2. Its lead program is AT2221 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Amicus Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Amicus Therapeutics, Inc. (FOLD) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track FOLD biotech catalysts?→
Add FOLD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Amicus Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.